ADVA Biotechnology

Company Overview

Snapshot

Founded in September 2016 by Tal Slonim, Ron Elazary-Vulcani, Barbara Paldus, and Ohad Karnieli, ADVA Biotechnology operates with 11–50 employees. The company has secured funding across three rounds from AGP Ventures and ExitValley. In August 2022, ADVA Biotechnology and Lonza agreed to expand the availability and use of automated bioreactors, including a license to Lonza's patents.

Business overview

ADVA Biotechnology develops enabling technologies for cell therapy manufacturing, focusing on an automated platform for autologous cell manufacturing. Its core product, ADVA X3, is a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution. This technology aims to optimize autologous cell therapy manufacturing at the bedside, improving availability, reducing time to market, and significantly cutting costs. The platform is designed for flexibility, allowing the manufacturing of various cell types by changing the disposable chamber. The company operates within the Health Tech & Life Sciences sector, serving markets related to medical technologies, biotechnology, and cancer treatment.

Strategic signal

In August 2022, ADVA Biotechnology and Lonza announced an agreement to expand the availability and use of automated bioreactors, which includes a license to Lonza's patents. This collaboration signals a significant step towards broader adoption and validation of ADVA Biotechnology's manufacturing technology within the cell therapy industry, suggesting potential for increased market penetration and strategic partnerships.

Company Intelligence Q&A

What is ADVA Biotechnology's primary focus?

ADVA Biotechnology focuses on developing enabling technologies for cell therapy manufacturing, specifically an automated platform for autologous cell manufacturing.

What is the ADVA X3 system?

The ADVA X3 is ADVA Biotechnology's robust, modular cell-manufacturing cGMP system, designed as a single-use end-to-end solution for autologous cell therapy manufacturing at the bedside.

When was ADVA Biotechnology founded?

ADVA Biotechnology was founded in September 2016.

Which companies partnered with ADVA Biotechnology in 2022?

In August 2022, ADVA Biotechnology and Lonza agreed to expand the availability and use of automated bioreactors, including a license to Lonza's patents.

Has ADVA Biotechnology received any grants?

In September 2024, ADVA Biotechnology secured a grant from the Israel Innovation Authority.